AbbVie Declares $1.64 Quarterly Dividend; 3.1% Yield
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
AbbVie Inc (ABBV)
AbbVie Inc stock price live, this page displays NYSE ABBV stock exchange data. View the ABBV premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the AbbVie Inc real time stock price chart below.
What Is the AbbVie Inc Stock Price Today?
The AbbVie Inc stock price today is 210.13.
What Is the Stock Symbol for AbbVie Inc?
The stock symbol for AbbVie Inc is ""ABBV.""
What Stock Exchange Does AbbVie Inc Trade On?
AbbVie Inc is listed and trades on the NYSE stock exchange.
Is AbbVie Inc a Good Stock to Buy?
Determining whether AbbVie Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABBV quote. (ISIN: US00287Y1091)
What Is the AbbVie Inc Stock Price Today?
The AbbVie Inc stock price today is 210.13.
What Is the Stock Symbol for AbbVie Inc?
The stock symbol for AbbVie Inc is ""ABBV.""
What Stock Exchange Does AbbVie Inc Trade On?
AbbVie Inc is listed and trades on the NYSE stock exchange.
Is AbbVie Inc a Good Stock to Buy?
Determining whether AbbVie Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABBV quote. (ISIN: US00287Y1091)
Fair Value
An estimate of a AbbVie's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
207.61
212.00
52 wk Range
163.81
218.66
ABBV Scorecard
Full Analysis
Has raised its dividend for 13 consecutive years
ABBV is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a AbbVie's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
207.61212.00
52 wk Range
163.81218.66
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.09%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.09%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABBV Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a AbbVie's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
216.48
Upside
+3.19%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
AbbVie Inc Company Profile
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc SWOT Analysis
Immunology Powerhouse | AbbVie's Skyrizi and Rinvoq drive growth, offsetting Humira's decline. Combined revenue projected to exceed $31 billion by 2027, showcasing strong market position. |
Pipeline Potential | Explore AbbVie's robust pipeline, including emraclidine for schizophrenia. Strategic acquisitions and upcoming clinical trials promise to diversify revenue streams. |
Analyst Optimism | Wall Street bullish on AbbVie's prospects. Price targets range from $195 to $240, with majority rating stock as Outperform or Overweight. |
Navigating Challenges | Delve into AbbVie's strategies for managing biosimilar competition, pricing pressures, and market dynamics in aesthetics business to maintain industry leadership. |
AbbVie Inc Earnings Call Summary for Q2/2025
- AbbVie beats Q2 2025 expectations with EPS of $2.97 and revenue of $15.4B, leading to 4.76% stock surge in pre-market trading
- Full-year revenue guidance raised to $60.5B, with strong performance from SKYRIZI and RINVOQ driving growth
- CEO Rob Michael emphasizes strong outlook and goal to become largest neuroscience company in the industry next year
- Company faces challenges in aesthetics market and potential competition from Stelara biosimilars
- AbbVie maintains strong financial health with impressive profit margins and consistent dividend growth
Last Updated: 31/07/2025, 18:08
Read Full TranscriptCompare ABBV to Peers and Sector
Metrics to compare | ABBV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABBVPeersSector | |
|---|---|---|---|---|
P/E Ratio | 99.0x | −6.8x | −0.6x | |
PEG Ratio | −3.39 | −0.21 | 0.00 | |
Price/Book | −2,013.7x | 2.2x | 2.6x | |
Price / LTM Sales | 6.3x | 6.1x | 3.3x | |
Upside (Analyst Target) | 1.1% | 27.5% | 38.0% | |
Fair Value Upside | Unlock | 20.0% | 4.3% | Unlock |
Analyst Ratings
18 Buy
10 Hold
0 Sell
Ratings:
28 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 216.48
(+3.19% Upside)
Earnings
Latest Release
Jul 31, 2025
EPS / Forecast
2.97 / 2.96
Revenue / Forecast
15.42B / 14.99B
People Also Watch
FAQ
What Stock Exchange Does AbbVie Trade On?
AbbVie is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for AbbVie?
The stock symbol for AbbVie is "ABBV."
What Is the AbbVie Market Cap?
As of today, AbbVie market cap is 370.39B.
What Is AbbVie's Earnings Per Share (TTM)?
The AbbVie EPS (TTM) is 2.11.
When Is the Next AbbVie Earnings Date?
AbbVie will release its next earnings report on 23 Oct 2025.
From a Technical Analysis Perspective, Is ABBV a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has AbbVie Stock Split?
AbbVie has split 0 times.
How Many Employees Does AbbVie Have?
AbbVie has 55000 employees.
What is the current trading status of AbbVie (ABBV)?
As of 08 Sept 2025, AbbVie (ABBV) is trading at a price of 209.79, with a previous close of 212.56. The stock has fluctuated within a day range of 207.61 to 212.00, while its 52-week range spans from 163.81 to 218.66.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.